Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 2;17(11):4102-4104.
doi: 10.1080/21645515.2021.1976036. Epub 2021 Oct 7.

An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report

Wumeng Jin  1 , Yujun Tang  1 , Chengping Wen  1
Affiliations
Case Reports

An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report

Wumeng Jin et al. Hum Vaccin Immunother. .

Abstract

After the COVID-19 pandemic, vaccines using inactivated viruses have attracted worldwide attention for the prevention of infectious diseases. Here, we report a patient who suffered from Systemic Lupus Erythematosus (SLE) for six years and developed ocular symptoms within 72 hours after being vaccinated for COVID-19. The patient presented bilateral conjunctival congestion, eyelid edema with pruritus, and suffered from severe headaches. Recovery occurred within 10 days after the onset of symptoms after treatment with anti-infection drugs. The early identification and extensive assessment of side effects help ensuring effective vaccine safety monitoring.

Keywords: COVID-19 vaccine; case report; ocular adverse reactions; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Images of left eye of a 28-year-old female who developed an acute ocular symptoms 3 days after COVID-19 vaccination.
Figure 2.
Figure 2.
Disease timeline sequence of symptoms and examinations.
Figure 3.
Figure 3.
Ultrasonographic images of the eyes revealed vitreous opacity and staphyloma of the posterior sclera in both eyes, but no obvious retinal detachment.
See this image and copyright information in PMC

References

    1. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde M, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853. - PMC - PubMed
    1. Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, Chen HX. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20:891–98. - PMC - PubMed
    1. Silpa-Archa S, Lee JJ, Foster CS.. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100:135–41. doi: 10.1136/bjophthalmol-2015-306629. - DOI - PubMed
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rhumatol. 2002;29:288–91. - PubMed
    1. Bonilla FA. Update: vaccines in primary immunodeficiency. J Allergy Clin Immunol. 2018;141:474–81. doi: 10.1016/j.jaci.2017.12.980. - DOI - PubMed

Publication types

Substances